Takeda, Mylan Reach Agreement Over Prevacid Generic

Law360, New York (July 11, 2011, 8:01 PM ET) -- Mylan Inc. on Friday exited a New Jersey suit brought by Takeda Pharmaceutical Co. Ltd. over a generic version of acid reflex drug Prevacid, though one of the generics maker's subsidiaries remains as a defendant.

The settlement agreement, signed by U.S. District Judge Joel A. Pisano, dismisses Mylan as a defendant but a unit of the drugmaker, Mylan Pharmaceuticals Inc., remains in the suit.

Takeda accuses Mylan of infringing its two patents covering Prevacid by filing an abbreviated new drug application to get U.S. Food and...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required